Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Share-based Compensation: 2009-2024

Historic Share-based Compensation for Ani Pharmaceuticals (ANIP) over the last 15 years, with Dec 2024 value amounting to $29.3 million.

  • Ani Pharmaceuticals' Share-based Compensation rose 29.47% to $9.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.2 million, marking a year-over-year increase of 26.23%. This contributed to the annual value of $29.3 million for FY2024, which is 42.09% up from last year.
  • Ani Pharmaceuticals' Share-based Compensation amounted to $29.3 million in FY2024, which was up 42.09% from $20.7 million recorded in FY2023.
  • Ani Pharmaceuticals' 5-year Share-based Compensation high stood at $29.3 million for FY2024, and its period low was $10.5 million during FY2021.
  • In the last 3 years, Ani Pharmaceuticals' Share-based Compensation had a median value of $20.7 million in 2023 and averaged $21.5 million.
  • Per our database at Business Quant, Ani Pharmaceuticals' Share-based Compensation declined by 18.92% in 2021 and then surged by 42.09% in 2024.
  • Ani Pharmaceuticals' Share-based Compensation (Yearly) stood at $12.9 million in 2020, then fell by 18.92% to $10.5 million in 2021, then soared by 39.18% to $14.6 million in 2022, then soared by 41.46% to $20.7 million in 2023, then spiked by 42.09% to $29.3 million in 2024.